GH prevents adipogenic differentiation of mesenchymal stromal stem cells derived from human trabecular bone via canonical Wnt signaling

Bolamperti, Simona; Signo, Michela; Spinello, Alice; Moro, Giorgio; Fraschini, G.; Guidobono, F.; Rubinacci, Alessandro; Villa, Isabella

doi:10.1016/j.bone.2018.04.014

Cited by 21 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This fact has also been confirmed in MSCs of human trabecular bones. Human bone marrow MSCs express GHR and respond to GH via JAK2/STAT5 intracellular signaling [154]. These findings support the idea that MSC activity might be modulated with independence of the origin of these cells and that GH can be a true stimulator for them.…”

Section: Gh and Mesenchymal Stem Cells (Mscs)supporting

confidence: 75%

Why Should Growth Hormone (GH) Be Considered a Promising Therapeutic Agent for Arteriogenesis? Insights from the GHAS Trial

Caicedo

Devesa²,

Álvarez

et al. 2020

Cells

View full text Add to dashboard Cite

Despite the important role that the growth hormone (GH)/IGF-I axis plays in vascular homeostasis, these kind of growth factors barely appear in articles addressing the neovascularization process. Currently, the vascular endothelium is considered as an authentic gland of internal secretion due to the wide variety of released factors and functions with local effects, including the paracrine/autocrine production of GH or IGF-I, for which the endothelium has specific receptors. In this comprehensive review, the evidence involving these proangiogenic hormones in arteriogenesis dealing with the arterial occlusion and making of them a potential therapy is described. All the elements that trigger the local and systemic production of GH/IGF-I, as well as their possible roles both in physiological and pathological conditions are analyzed. All of the evidence is combined with important data from the GHAS trial, in which GH or a placebo were administrated to patients suffering from critical limb ischemia with no option for revascularization. We postulate that GH, alone or in combination, should be considered as a promising therapeutic agent for helping in the approach of ischemic disease.

show abstract

Section: Gh and Mesenchymal Stem Cells (Mscs)supporting

confidence: 75%

Why Should Growth Hormone (GH) Be Considered a Promising Therapeutic Agent for Arteriogenesis? Insights from the GHAS Trial

Caicedo

Devesa²,

Álvarez

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…This fact has also been confirmed in MSCs of human trabecular bone. Human bone marrow MSCs express GHR and respond to GH via JAK2/STAT5 intracellular signaling [176]. These findings support the idea that MSCs activity might be modulated with independence of the origin of these cells, and that GH can be a true stimulator for them.…”

Section: Gh and Mesenchymal Stem Cells (Mscs)supporting

confidence: 75%

Why Should Growth Hormone (GH) Be Considered a Promising Therapeutic Agent for Arteriogenesis? Insights from the GHAS Trial

Caicedo¹,

Devesa²,

Álvarez³

et al. 2019

Preprint

View full text Add to dashboard Cite

Despite the important role that the GH/IGF-I axis plays in vascular homeostasis, these kind of growth factors barely appear in articles addressing the neovascularization process. Currently, the vascular endothelium has turned to be considered as an authentic gland of internal secretion due to the wide variety of released factors and functions with local effect, including the paracrine/autocrine production of GH or IGF-I, for which the endothelium has specific receptors. In this comprehensive review, it will be described the evidence involving these proangiogenic hormones in arteriogenesis dealing with the arterial occlusion and making of them a potential therapy. It will be analyzed all those elements triggering the local and systemic production of GH/IGF-I and their possible role both in physiological and pathological conditions. The whole evidence will be combined with important data from the GHAS trial, in which GH or placebo were administrated to patients suffering from critical limb ischemia with no option for revascularization. We postulate that GH, alone or in combination, should be considered as a promising therapeutic agent for helping in the approach of the ischemic disease.A normal embryonic development needs the formation of blood vessels [21]; after birth there is also the need of the formation of new blood vessels while growing, but also in some physiological processes such as the menstrual cycle in women and the development of the mammary gland during pregnancy [22], but apart from these situations, adult neovascularization rarely takes place and when it happens it is associated with pathological affectations, such as wounds, muscle injuries, fractures or hypoxia/ischemia. The question now would be: how does neovascularization occur in adults and what is the role of the GH / IGF-I system in it?As it seems logical, hypoxia is a very important stimulus for the growth of new blood vessels [23], triggering this growth through hypoxia-inducible factors (HIF) that act on the expression of proangiogenic factors, but also that of anti-angiogenic factors to achieve the perfect number and size of the vessels necessary to compensate for the lack of oxygen supply and to regenerate the tissue [23]. This is a clear and well-established fact for angiogenesis. However, when a progressive narrowing of the vascular lumen appears, preexisting collaterals will have to growth to compensate the lack of distal flow which is triggered in a totally different way. With independence of that, the stimulation of endothelial nitric oxide synthase (eNOS) that leads to the production of nitric oxide (NO) from the vascular endothelium seems to be the key mediator for both kind of reparative processes. NO is a potent vasodilator, therefore increasing blood supply to the zone affected by hypoxia/ischemia. This implies changes in the vascular tone, vasorelaxation and vasopermeability, which are affected in arteries suffering an atherosclerotic damage. Interestingly, GH activates the NO pathway [14,24] throughout direct mechanisms tha...

show abstract

“…The Wnt signaling pathway is highly conserved and restrains adipocyte differentiation by weakening the differentiation of bone marrow stromal cells. If the signal pathway is disordered, obesity can occur in the body (Bolamperti et al., ). PPARs include α, β, γ3, and subtypes.…”

Section: Resultsmentioning

confidence: 99%

Effects of Lactobacillus Casei YBJ02 on Lipid Metabolism in Hyperlipidemic Mice

Qian

Wang

et al. 2019

Journal of Food Science

View full text Add to dashboard Cite

Traditionally fermented yak yogurt as a Tibetan dairy product is high not only in nutrients but also in probiotics. A probiotic strain with a potential lipid reducing effect was isolated from yak yogurt. An animal model for hyperlipidemia was evaluated using the blood index and expression levels of lipid metabolism-related proteins in mice to determine the effect of Lactobacillus casei YBJ02 (LC-YBJ02) on lipid metabolism in hyperlipidemic mice and the underlying mechanism. LC-YBJ02 at different concentrations exhibited certain inhibitory effects on the increase in blood lipid in mice. Particularly, high concentrations of LC-YBJ02 can reduce the cholesterol, triglycerides, and low-density lipoprotein content; however, no significant effect on the high-density lipoprotein of the body has been reported. LC-YBJ02 can effectively increase the reduction in cholesterol level by fecal excretion. In this study, the gene-affecting mouse obesity was determined using experimental results in mice. The expression levels of peroxisome proliferator-activated receptor γ (PPARγ ), CCAAT enhancer binding protein alpha (CEBP)/α, sterol regulatory element binding protein (SREBP)-1c, and FAS could improve because of the high-fat diet in kidney fat. Bacteria at different concentrations could also decrease these expression levels. Specifically, the high concentration of LC-YBJ02 could suppress the expression of PPARγ , CEBP/α, and SREBP-1c; however, the expression of FAS was not significantly inhibited. PPARγ and FAS expression levels in the liver were low, but no significant difference was indicated. CEBP/α and SREBP-1c expression in mouse liver was further detected by Western blot analysis; CEBP/α was considerably low and could not be detected. On the basis of these results, LC-YBJ02 could be used as probiotics through its lipid reduction effects.

show abstract

GH prevents adipogenic differentiation of mesenchymal stromal stem cells derived from human trabecular bone via canonical Wnt signaling

Cited by 21 publications

References 37 publications

Why Should Growth Hormone (GH) Be Considered a Promising Therapeutic Agent for Arteriogenesis? Insights from the GHAS Trial

Why Should Growth Hormone (GH) Be Considered a Promising Therapeutic Agent for Arteriogenesis? Insights from the GHAS Trial

Why Should Growth Hormone (GH) Be Considered a Promising Therapeutic Agent for Arteriogenesis? Insights from the GHAS Trial

Effects of Lactobacillus Casei YBJ02 on Lipid Metabolism in Hyperlipidemic Mice

Contact Info

Product

Resources

About